Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.
about
Osteonecrosis in children with acute lymphoblastic leukemiaPharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapyHow I treat acute lymphoblastic leukemia in older adolescents and young adultsNon-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.Bone morbidity in childhood leukemia: epidemiology, mechanisms, diagnosis, and treatmentGlucocorticoid-induced osteonecrosis.Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia.A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemiaThe BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids.Impairments that influence physical function among survivors of childhood cancerEffect of premedications in a murine model of asparaginase hypersensitivityEvidence for age as a modifier of genetic associations for lipid levels.Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivorsChallenging issues in pediatric oncologyLessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.Genome-wide single-nucleotide polymorphism analysis revealed SUFU suppression of acute graft-versus-host disease through downregulation of HLA-DR expression in recipient dendritic cells.Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.Inherited genetic variation in childhood acute lymphoblastic leukemia.Screening and management of adverse endocrine outcomes in adult survivors of childhood and adolescent cancer.Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse ModelAcute Activation of Metabolic Syndrome Components in Pediatric Acute Lymphoblastic Leukemia Patients Treated with Dexamethasone.Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemiaPharmacogenomics of adverse effects of anti-leukemic agents in children.Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trialAggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemiaWidespread osteonecrosis in children with leukemia revealed by whole-body MRI.Osteonecrosis in children after therapy for malignancy.Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.Substrain-specific differences in survival and osteonecrosis incidence in a mouse model.Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia.Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer InstitutIncidence and outcome of osteonecrosis in children and adolescents after intensive therapy for acute lymphoblastic leukemia (ALL).Milestones in the curability of pediatric cancersSymptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood.Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis.The adolescent and young adult with cancer: state of the art-- acute leukemias.Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232
P2860
Q28066799-B50F30B4-D922-466F-ABEF-222DF2A37CD3Q28083449-C6EC4A8F-0B48-4C5A-9CAE-B207F8CB0CFFQ28087589-42642E45-C395-4B3B-9208-5051E3B66490Q33557148-623D0C33-875B-4950-9A24-E18B49F78001Q34026481-37AD2E8F-E976-40FC-B9A4-63F8A6A2893BQ34038283-5AC8DC22-43B6-455F-A54F-CA0F2B94262EQ34240713-106A9071-1A84-4958-8159-C5738060845AQ34267235-0C4E7687-5815-4C0B-97D3-64C557E5E559Q34448969-0413E538-B283-49D7-95CB-CB0D1A943826Q35006917-31AF79A0-D7D3-46C8-B6A9-4C30B08B0107Q35065477-D587C400-177C-43FE-A204-1954AB78FA47Q35082766-61AC068F-5A25-4AA8-A0BD-E4B92B84704EQ35156439-092BD9CD-8C31-4CA0-9C09-DC08D855E348Q35162899-F8E55FA6-A0EA-4390-879B-4DFFB42A5E53Q35327266-C46A2E15-A185-41DD-8D5D-0BE6C2888BB5Q35602419-8723CFD1-59E3-4754-BDF4-7695FB4BA1D3Q35667279-1EC05830-FCBB-4077-BD6D-CCDFD010DB4FQ35726310-3A499940-5CD3-44EE-B619-40A7E37A95B0Q35740019-74D1D0AD-7F48-41A8-B65E-8ABDB27884D6Q35776973-B099E0CE-D2C1-4BE4-BE7F-533EC8A2D07EQ35784497-B5AF680D-54C4-465A-9AE1-1E15AC6E26F3Q35815806-5498B347-E04C-45CA-ABE6-193CFBCD1F60Q35954058-59473538-5FE7-4D42-8DA0-9D16A06FD837Q36064796-C2C68E6D-C464-4DBE-A1BB-E0959C310644Q36143232-3F906CEF-1CF1-45CD-9668-D687A03947C8Q36191097-FFAB4316-1862-4F73-8FCB-58BD1C154AF9Q36251056-8962440D-F2C9-457B-A2C7-C820F1E91A3EQ36337592-6E3D4087-95B8-4008-896A-69CDEC6B7231Q36381725-C62FC627-2B1C-43A6-81DB-CB176B50CEF7Q36429353-2C119FC2-6BBA-454B-A4E1-391C6EE5A632Q36452241-16606936-F8CE-4EDB-A837-AE848A9C694BQ36481285-5B9772A8-C179-4803-826D-6F2229BE43DFQ36547791-BC9E8A69-788E-41FC-AC19-FA0B5B9F9FD8Q36678136-F267CAF8-74BC-45E1-95D7-ACF0D4E24A60Q36895136-4EDB9D66-CEA8-47C2-ACB3-55EE278FE461Q36925083-7DDB3832-DFCA-4F90-BCDF-03B31FDDFF7BQ36967138-26FE1FA2-9D77-4462-B50D-F294A730B47CQ36986496-D8BBFACD-DEC5-4CD5-AFA2-1FAFE4245A8EQ37134753-400FA69E-304E-48FF-8288-68C5A81BD467Q37169331-6AF17DE8-59D9-44B8-B5CB-347A04190A3D
P2860
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.
@ast
Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.
@en
Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.
@nl
type
label
Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.
@ast
Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.
@en
Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.
@nl
prefLabel
Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.
@ast
Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.
@en
Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P1433
P1476
Pharmacokinetic, pharmacodynam ...... acute lymphoblastic leukemia.
@en
P2093
Cheng Cheng
Deqing Pei
Geoffrey Neale
Jitesh D Kawedia
John C Panetta
Mary V Relling
Scott C Howard
Sue C Kaste
William E Evans
Xiangjun Cai
P2860
P304
2340-7; quiz 2556
P356
10.1182/BLOOD-2010-10-311969
P407
P577
2010-12-10T00:00:00Z